about
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivinGREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancerProfile of palbociclib in the treatment of metastatic breast cancerRoles for miRNAs in endocrine resistance in breast cancerGenomic and non-genomic effects of glucocorticoids: implications for breast cancerMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerEstrogen-Related Receptors in Breast Cancer and Prostate CancerEnhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling PathwaysInhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistanceTamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerRegulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane rufflingTranscriptional regulation prediction of antiestrogen resistance in breast cancer based on RNA polymerase II binding data.A transgenic mouse model expressing an ERα folding biosensor reveals the effects of Bisphenol A on estrogen receptor signaling.Small optic cup sizes among women using tamoxifen: assessment with scanning laser ophthalmoscopy.Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programsAurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells.5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer.Development of an image analysis screen for estrogen receptor alpha (ERα) ligands through measurement of nuclear translocation dynamicsStapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics.Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism.Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation.Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.CAPER, a novel regulator of human breast cancer progression.Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cellsThe NF1 somatic mutational landscape in sporadic human cancers.Investigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy.Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription.Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3) is predicted to interact with its partner through an ARM-type α-helical structurePictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.Genotype-guided tamoxifen therapy: time to pause for reflection?Progesterone receptor action: defining a role in breast cancerDEAD-box helicase DP103 defines metastatic potential of human breast cancers.The Effects of Tamoxifen in Combination with Tranilast on CXCL12-CXCR4 Axis and Invasion in Breast Cancer Cell Lines.Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole
P2860
Q21195209-6FB8F80D-BE17-408C-B63F-CAEB21B4B2A8Q21560759-BB05BA04-D5D2-4A1A-BFE9-F57385B26B2EQ26747737-AB2DB66B-341C-4696-98E8-6667A60B2EA2Q26783076-1BD76393-4E47-4355-A9A1-4A0C9834F2F0Q26851382-546E54C3-F2DF-46AB-A1BD-8BCD8C74E1E7Q27001260-5C5875A9-5124-45EC-8ADF-F8382E571D3AQ28084030-A9E7798B-B102-4B84-8322-6795DCB766F2Q28084585-CBED0C40-5042-4C27-A472-A1FBF239FA54Q28237217-DC694962-37A3-455B-B4F9-2EDE5BF16214Q28481232-DB6AA1F4-DCD3-463F-BABF-0C035243CD5FQ28569016-FCD46E11-8F37-4635-A9E6-B173C745207DQ30411760-5D6842B5-05AC-4C28-8AE3-3AD390DE3AA3Q30763243-473086EB-B82A-4D40-B71A-0DA759B8D52CQ30819855-B4AC7FAE-E7B0-4812-A4FA-4CADE90D5616Q33239343-6CC46CA6-8BE5-4604-B06F-0082B57968EAQ33441090-170466A0-5959-44F6-9135-1DA0281CEE7AQ33568421-FDBC888A-C133-4F70-A979-57DC0C4A649DQ33591225-3C293EE7-7C84-411B-B575-3599817DF1F2Q33612962-AEEB385C-3228-4B88-B4AA-C00B77CF8944Q33662031-AB7C39A4-1DC5-499A-B0D3-1F005D70FC57Q33684356-1F299B69-8F1E-4472-ADAA-3FEB141EFDF4Q33687329-8277FA14-FFAB-4276-AB7F-396A8B1C31E7Q33703311-445FA513-8F34-4D8D-8319-317256EDD27AQ33703811-ACDFD741-6EF7-46AC-94A3-755690E590ABQ33723377-D5AEB057-AF03-406C-A260-C40F84A24706Q33727026-EEE87BF5-F7BA-4059-86E7-FAC5391EB27EQ33728372-C18C3023-BAE0-4E59-AAF8-E9D36FB7315EQ33745649-E7710EEA-854B-447C-9612-48D5B91DBC45Q33754852-70FFF6B3-19E7-4B5F-B19F-BBEC0A9432D4Q33759701-0CC12AB0-8C73-448C-8838-DBA71E59578AQ33823452-786A023D-955B-45BE-8CC1-A3FF70B4CDBFQ33828887-E8FAF0FD-8E11-453D-907E-3C6A99965A5FQ33872793-3BC72B46-EEBF-48FA-B215-5CA31DE5ABCBQ33896624-EAEDF363-450A-4DF9-9B11-C6F8FDF00C6AQ33925164-251BB1A8-292D-4A18-B243-D8FDC372A426Q33955759-9E646880-0ED5-416E-B16C-60535D17B18FQ33998721-18C4BEE6-681B-48C4-9A6A-E8B3869BA78CQ34117601-DF0A8F1C-EFE0-4BC1-A4FC-C465C1F7A769Q34146185-1CC9CB95-DBFE-4E9E-9DD7-D2E48855DA64Q34173468-00A38FA3-3F6E-45A8-9F66-BE2ECB9160BB
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Mechanisms of tamoxifen resistance.
@ast
Mechanisms of tamoxifen resistance.
@en
Mechanisms of tamoxifen resistance.
@nl
type
label
Mechanisms of tamoxifen resistance.
@ast
Mechanisms of tamoxifen resistance.
@en
Mechanisms of tamoxifen resistance.
@nl
prefLabel
Mechanisms of tamoxifen resistance.
@ast
Mechanisms of tamoxifen resistance.
@en
Mechanisms of tamoxifen resistance.
@nl
P356
P1476
Mechanisms of tamoxifen resistance.
@en
P2093
Alistair Ring
P304
P356
10.1677/ERC.1.00776
P577
2004-12-01T00:00:00Z